V.F.Snegirev Archives of Obstetrics and GynecologyV.F.Snegirev Archives of Obstetrics and GynecologyАрхив акушерства и гинекологии им. В.Ф. Снегирева2313-87262687-1386Eco-Vector11102810.17816/2313-8726-2022-9-3-133-142ReviewsНаучные обзорыReview ArticleProspects for the use of biochemical markers in placental in-growthПерспективы использования биохимических маркеров при врастании плацентыhttps://orcid.org/0000-0003-2645-1662YashchukAl’fiya G.ЯщукАльфия Галимовна
Russian Federation

MD, Dr. Sci. (Med.), Professor

д.м.н., профессор

alfiya_galimovna@mail.ruhttps://orcid.org/0000-0001-5520-5845MusinIl’nur I.МусинИльнур Ирекович
Russian Federation

MD, Cand. Sci. (Med.), Assistant Professor

к.м.н., доцент

ilnur-musin@yandex.ruhttps://orcid.org/0000-0002-2028-7796BergEhdvard A.БергЭдвард Александрович
Russian Federation

Assistant Lecturer

ассистент

nucleardeer@gmail.comhttps://orcid.org/0000-0001-5638-1779GromenkoDar’ya D.ГроменкоДарья Дмитриевна
Russian Federation

student

студентка

dasha.gromenko@mail.ruhttps://orcid.org/0000-0003-3799-4080YanbarisovaAliya R.ЯнбарисоваАлия Ринатовна
Russian Federation

student

студентка

yanbarisova1999@mail.ruhttps://orcid.org/0000-0001-8582-660XGromenkoIvan D.ГроменкоИван Дмитриевич
Russian Federation

Assistant Lecturer

ассистент

z28ivan@mail.ruhttps://orcid.org/0000-0002-5111-0256BerdigulovaEhnzhe F.БердигуловаЭнже Филюсовна
Russian Federation

student

студентка

berdigulova_enzhe@mail.ruBashkir State Medical UniversityБашкирский государственный медицинский университет23092022931331422309202223092022Copyright ©; 2022, Eco-VectorCopyright ©; 2022, ООО "Эко-Вектор"2022Eco-VectorООО "Эко-Вектор"https://archivog.com/2313-8726/article/view/111028

Placental in-growth is a severe obstetric pathology characterized by invasive placentation and associated with a high-risk of life-threatening hemorrhage. Despite the widespread use of instrumental methods of examination, timely diagnosis of placental in-growth is a challenging issue. Here, we reviewed the existing biochemical markers used for early detection and confirmation of placental in-growth, their specificity and sensitivity, and correlation with gestational age. Significant results were found for the following substances: pregnancy-associated plasma protein A (PAPP-A) in the first trimester, alpha-fetoprotein (AFP) and human beta-chorionic gonadotropin (Beta-hCG) in the second trimester, brain natriuretic peptide, antithrombin III, plasminogen activator inhibitor type I, soluble Tie-2 receptor (endothelial cell-specific tyrosine kinase receptor), and soluble vascular endothelial growth factor receptor-2. Our findings support the use of the aforementioned biomarkers as screening method for placental in-growth in medical practice.

Врастание плаценты ― тяжёлая акушерская патология, характеризующаяся инвазивной плацентацией и связанная с высоким риском опасной для жизни массивной кровопотери. Несмотря на широкое применение инструментальных методов исследования, своевременная диагностика врастания плаценты до настоящего времени остаётся не решённой проблемой. В данной статье рассмотрены основные существующие биохимические маркеры, которые могут быть использованы для раннего выявления и подтверждения диагноза «врастание плаценты», их специфичность и чувствительность, а также корреляция со сроком беременности. Значимые результаты были установлены для следующих веществ: ассоциированный с беременностью протеин А плазмы (РАРР-А) в первом триместре, альфа-фетопротеин (АФП) и бета-хорионический гонадотропин человека (β-ХГЧ) во втором триместре, мозговой натрийуретический пептид, антитромбин III, ингибитор активатора плазминогена I, растворимый Tie-2 (специфичный для эндотелиальных клеток рецептор тирозинкиназы), растворимый рецептор-2 фактора роста эндотелия сосудов. Полученные данные могут свидетельствовать в пользу потенциального использования вышеназванных биомаркеров в медицинской практике в качестве скринингового метода исследования врастания плаценты.

placental in-growthreviewbiochemical markerspregnancy-associated plasma protein Ahuman beta-chorionic gonadotropinhyperglycosylated human chorionic gonadotropinalpha-fetoproteinврастание плацентыобзорбиохимические маркерыассоциированный с беременностью протеин А плазмы PAPP-Абета-хорионический гонадотропин человека β-ХГЧгипергликозилированный ХГЧальфа-фетопротеин АФПCommittee on Obstetric Practice. Committee opinion no. 529: placenta accreta. Obstet Gynecol. 2012;120(1):207–211. doi: 10.1097/AOG.0b013e318262e340Committee on Obstetric Practice. Committee opinion no. 529: placenta accreta // Obstet Gynecol. 2012. Vol. 120, N 1. P. 207–211. doi: 10.1097/AOG.0b013e318262e340Higgins MF, Monteith C, Foley M, O’Herlihy C. Real increasing incidence of hysterectomy for placenta accreta following previous caesarean section. Eur J Obstet Gynecol Reprod Biol. 2013;171(1):54–56. doi: 10.1016/j.ejogrb.2013.08.030Higgins M.F., Monteith C., Foley M., O’Herlihy C. Real increasing incidence of hysterectomy for placenta accreta following previous caesarean section // Eur J Obstet Gynecol Reprod Biol. 2013. Vol. 171, N 1. P. 54–56. doi: 10.1016/j.ejogrb.2013.08.030Hull AD, Moore TR. Multiple repeat cesareans and the threat of placenta accreta: incidence, diagnosis, management. Clin Perinatol. 2011;38(2):285–296. doi: 10.1016/j.clp.2011.03.010Hull A.D., Moore T.R. Multiple repeat cesareans and the threat of placenta accreta: incidence, diagnosis, management // Clin Perinatol. 2011. Vol. 38, N 2. P. 285–296. doi: 10.1016/j.clp.2011.03.010Polikarpov AV, Aleksandrova GA, Golubev NA, et al. Main indicators of maternal and child health, the service activities of child welfare and obstetrics in the Russian Federation. Moscow; 2018. (In Russ).Поликарпов А.В., Александрова Г.А., Голубев Н.А., и др. Основные показатели здоровья матери и ребёнка, деятельность службы охраны детства и родовспоможения в Российской Федерации. Москва, 2018. 107 с.Polikarpov AV, Aleksandrova GA, Golubev NA, et al. Main indicators of maternal and child health, the service activities of child welfare and obstetrics in the Russian Federation. Moscow; 2019. (In Russ).Поликарпов А.В., Александрова Г.А., Голубев Н.А., и др. Основные показатели здоровья матери и ребёнка, деятельность службы охраны детства и родовспоможения в Российской Федерации. Москва, 2019. 107 с.Publications Committee, Society for Maternal-Fetal Medicine; Belfort MA. Placenta accreta. Am J Obstet Gynecol. 2010;203(5):430–439. doi: 10.1016/j.ajog.2010.09.013Publications Committee, Society for Maternal-Fetal Medicine; Belfort M.A. Placenta accreta // Am J Obstet Gynecol. 2010. Vol. 203, N 5. P. 430–439. doi: 10.1016/j.ajog.2010.09.013Pan XY, Wang YP, Zheng Z, et al. A Marked Increase in Obstetric Hysterectomy for Placenta Accreta. Chin Med J. (Engl). 2015;128(16):2189–2193. doi: 10.4103/0366-6999.162508Pan X.Y., Wang Y.P., Zheng Z., et al. A Marked Increase in Obstetric Hysterectomy for Placenta Accreta // Chin Med J (Engl). 2015. Vol. 128, N 16. P. 2189–2193. doi: 10.4103/0366-6999.162508Russian Society of Obstetricians and Gynecologists, Russian Obstetrical Anesthesiologists and Intensivists Association, Federation of Anaesthesiologists and Reanimatologists. Prevention, management algorithm, anesthesia and intensive therapy for postpartum bleeding. Clinical guidelines. Moscow; 2018. (In Russ).Российское общество акушеров-гинекологов, Ассоциация акушерских анестезиологов-реаниматологов, Федерация анестезиологов и реаниматологов. Профилактика, алгоритм ведения, анестезия и интенсивная терапия при послеродовых кровотечениях. Клинические рекомендации. Москва, 2018.Jauniaux E, Bhide A. Prenatal ultrasound diagnosis and outcome of placenta previa accreta after cesarean delivery: a systematic review and meta-analysis. Am J Obstet Gynecol. 2017;217(1):27–36. doi: 10.1016/j.ajog.2017.02.050Jauniaux E., Bhide A. Prenatal ultrasound diagnosis and outcome of placenta previa accreta after cesarean delivery: a systematic review and meta-analysis // Am J Obstet Gynecol. 2017. Vol. 217, N 1. P. 27–36. doi: 10.1016/j.ajog.2017.02.050Jauniaux E, Bhide A, Kennedy A, et al. FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: Prenatal diagnosis and screening. Int J Gynaecol Obstet. 2018;140(3):274–280. doi: 10.1002/ijgo.12408Jauniaux E., Bhide A., Kennedy A., et al. FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: Prenatal diagnosis and screening // Int J Gynaecol Obstet. 2018. Vol. 140, N 3. P. 274–280. doi: 10.1002/ijgo.12408Finberg HJ, Williams JW. Placenta accreta: prospective sonographic diagnosis in patients with placenta previa and prior cesarean section. J Ultrasound Med. 1992;11(7):333–343. doi: 10.7863/jum.1992.11.7.333Finberg H.J., Williams J.W. Placenta accreta: prospective sonographic diagnosis in patients with placenta previa and prior cesarean section // J Ultrasound Med. 1992. Vol. 11, N 7. P. 333–343. doi: 10.7863/jum.1992.11.7.333Comstock CH, Love JJ Jr, Bronsteen RA, et al. Sonographic detection of placenta accreta in the second and third trimesters of pregnancy. Am J Obstet Gynecol. 2004;190(4):1135–1140. doi: 10.1016/j.ajog.2003.11.024Comstock C.H., Love J.J. Jr, Bronsteen R.A., et al. Sonographic detection of placenta accreta in the second and third trimesters of pregnancy // Am J Obstet Gynecol. 2004. Vol. 190, N 4. P. 1135–1140. doi: 10.1016/j.ajog.2003.11.024Zosmer N, Jauniaux E, Bunce C, et al. Interobserver agreement on standardized ultrasound and histopathologic signs for the prenatal diagnosis of placenta accreta spectrum disorders. Int J Gynaecol Obstet. 2018;140(3):326–331. doi: 10.1002/ijgo.12389Zosmer N., Jauniaux E., Bunce C., et al. Interobserver agreement on standardized ultrasound and histopathologic signs for the prenatal diagnosis of placenta accreta spectrum disorders // Int J Gynaecol Obstet. 2018. Vol. 140, N 3. P. 326–331. doi: 10.1002/ijgo.12389Jauniaux E, Alfirevic Z, Bhide AG, et al. Royal College of Obstetricians and Gynaecologists. Placenta Praevia and Placenta Accreta: Diagnosis and Management: Green-top Guideline No. 27a. BJOG. 2019;126(1):e1–e48. doi: 10.1111/1471-0528.15306Jauniaux E., Alfirevic Z., Bhide A.G., et al. Royal College of Obstetricians and Gynaecologists. Placenta Praevia and Placenta Accreta: Diagnosis and Management: Green-top Guideline No. 27a // BJOG. 2019. Vol. 126, N 1. P. e1–e48. doi: 10.1111/1471-0528.15306American College of Obstetricians and Gynecologists; Society for Maternal-Fetal Medicine. Obstetric Care Consensus No. 7: Placenta Accreta Spectrum. Obstet Gynecol. 2018;132(6):e259–e275. doi: 10.1097/AOG.0000000000002983American College of Obstetricians and Gynecologists; Society for Maternal-Fetal Medicine. Obstetric Care Consensus No. 7: Placenta Accreta Spectrum // Obstet Gynecol. 2018. Vol. 132, N 6. P. e259–e275. doi: 10.1097/AOG.0000000000002983Bailit JL, Grobman WA, Rice MM, et al. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Morbidly adherent placenta treatments and outcomes. Obstet Gynecol. 2015;125(3):683–689. doi: 10.1097/AOG.0000000000000680Bailit J.L., Grobman W.A., Rice M.M., et al. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Morbidly Adherent Placenta Treatments and Outcomes // Obstet Gynecol. 2015. Vol. 125, N 3. P. 683–689. doi: 10.1097/AOG.0000000000000680Fitzpatrick KE, Sellers S, Spark P, et al. The management and outcomes of placenta accreta, increta, and percreta in the UK: a population-based descriptive study. BJOG. 2014;121(1):62–70; discus. 70–71. doi: 10.1111/1471-0528.12405Fitzpatrick K.E., Sellers S., Spark P., et al. The management and outcomes of placenta accreta, increta, and percreta in the UK: a population-based descriptive study // BJOG. 2014. Vol. 121, N 1. P. 62–70; discus. 70–71. doi: 10.1111/1471-0528.12405Thurn L, Lindqvist PG, Jakobsson M, et al. Abnormally invasive placenta-prevalence, risk factors and antenatal suspicion: results from a large population-based pregnancy cohort study in the Nordic countries. BJOG. 2016;123(8):1348–1355. doi: 10.1111/1471-0528.13547Thurn L., Lindqvist P.G., Jakobsson M., et al. Abnormally invasive placenta-prevalence, risk factors and antenatal suspicion: results from a large population-based pregnancy cohort study in the Nordic countries // BJOG. 2016. Vol. 123, N 8. P. 1348–1355. doi: 10.1111/1471-0528.13547Krantz D, Goetzl L, Simpson JL, et al. First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group. Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. Am J Obstet Gynecol. 2004;191(4):1452–1458. doi: 10.1016/j.ajog.2004.05.068Krantz D., Goetzl L., Simpson J.L., et al. First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group. Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes // Am J Obstet Gynecol. 2004. Vol. 191, N 4. P. 1452–1458. doi: 10.1016/j.ajog.2004.05.068Smith GCS, Stenhouse EJ, Crossley JA, et al. Early pregnancy levels of pregnancy-associated plasma protein A and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab. 2002;87(4):1762–1767. doi: 10.1210/jcem.87.4.8430Smith G.C.S., Stenhouse E.J., Crossley J.A., et al. Early pregnancy levels of pregnancy-associated plasma protein A and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth // J Clin Endocrinol Metab. 2002. Vol. 87, N 4. P. 1762–1767. doi: 10.1210/jcem.87.4.8430Desai N, Krantz D, Roman A, et al. Elevated first trimester PAPP-A is associated with increased risk of placenta accreta. Prenat Diagn. 2014;34(2):159–162. doi: 10.1002/pd.4277Desai N., Krantz D., Roman A., et al. Elevated first trimester PAPP-A is associated with increased risk of placenta accreta // Prenat Diagn. 2014. Vol. 34, N 2. P. 159–162. doi: 10.1002/pd.4277Thompson O, Otigbah C, Nnochiri A, Sumithran E, Spencer K. First trimester maternal serum biochemical markers of aneuploidy in pregnancies with abnormally invasive placentation. BJOG. 2015;122(10):1370–1376. doi: 10.1111/1471-0528.13298Thompson O., Otigbah C., Nnochiri A., Sumithran E., Spencer K. First trimester maternal serum biochemical markers of aneuploidy in pregnancies with abnormally invasive placentation // BJOG. 2015. Vol. 122, N 10. P. 1370–1376. doi: 10.1111/1471-0528.13298Büke B, Akkaya H, Demir S, et al. Relationship between first trimester aneuploidy screening test serum analytes and placenta accreta. J Matern Fetal Neonatal Med. 2018;31(1):59–62. doi: 10.1080/14767058.2016.1275546Büke B., Akkaya H., Demir S., et al. Relationship between first trimester aneuploidy screening test serum analytes and placenta accreta // J Matern Fetal Neonatal Med. 2018. Vol. 31, N 1. P. 59–62. doi: 10.1080/14767058.2016.1275546Penzhoyan GA, Makukhina TB. Significance of the routine first-trimester antenatal screening program for aneuploidy in the assessment of the risk of placenta accreta spectrum disorders. J Perinat Med. 2019;48(1):21–26. doi: 10.1515/jpm-2019-0261Penzhoyan G.A., Makukhina T.B. Significance of the routine first-trimester antenatal screening program for aneuploidy in the assessment of the risk of placenta accreta spectrum disorders // J Perinat Med. 2019. Vol. 48, N 1. P. 21–26. doi: 10.1515/jpm-2019-0261Borovkov VA. Poetapnoe prognozirovanie vrastaniya platsenty u zhenshchin s rubtsom na matke [dissertation]. Barnaul; 2020. Avai lable from: https://www.dissercat.com/content/poetapnoe-prognozirovanie-vrastaniya-platsenty-u-zhenshchin-s-rubtsom-na-matke? (In Russ).Боровков В.А. Поэтапное прогнозирование врастания плаценты у женщин с рубцом на матке : дис. … канд. мед. наук. Барнаул, 2020. Режим доступа: https://www.dissercat.com/content/poetapnoe-prognozirovanie-vrastaniya-platsenty-u-zhenshchin-s-rubtsom-na-matke? Дата обращения: 15.06.2022.Wang F, Chen S, Wang J, et al. First trimester serum PAPP-A is associated with placenta accreta: a retrospective study. Arch Gynecol Obstet. 2021;303(3):645–652. doi: 10.1007/s00404-020-05960-1Wang F., Chen S., Wang J., et al. First trimester serum PAPP-A is associated with placenta accreta: a retrospective study // Arch Gynecol Obstet. 2021. Vol. 303, N 3. P. 645–652. doi: 10.1007/s00404-020-05960-1Bartels HC, Postle JD, Downey P, Brennan DJ. Placenta Accreta Spectrum: A Review of Pathology, Molecular Biology, and Biomar kers. Dis Markers. 2018;2018:1507674. doi: 10.1155/2018/1507674Bartels H.C., Postle J.D., Downey P., Brennan D.J. Placenta Accreta Spectrum: A Review of Pathology, Molecular Biology, and Biomarkers // Dis Markers. 2018. Vol. 2018. P. 1507674. doi: 10.1155/2018/1507674Cole LA. Biological functions of hCG and hCG-related molecules. Reprod Biol Endocrinol. 2010;8(1):102. doi: 10.1186/1477-7827-8-102Cole L.A. Biological functions of hCG and hCG-related molecules // Reprod Biol Endocrinol. 2010. Vol. 8. P. 102. doi: 10.1186/1477-7827-8-102Berndt S, Perrier d’Hauterive S, Blacher S, et al. Angiogenic activity of human chorionic gonadotropin through LH receptor activation on endothelial and epithelial cells of the endometrium. FASEB J. 2006;20(14):2630–2632. doi: 10.1096/fj.06-5885fjeBerndt S., Perrier d’Hauterive S., Blacher S., et al. Angiogenic activity of human chorionic gonadotropin through LH receptor activation on endothelial and epithelial cells of the endometrium // FASEB J. 2006. Vol. 20, N 14. P. 2630–2632. doi: 10.1096/fj.06-5885fjeHandschuh K, Guibourdenche J, Tsatsaris V, et al. Human chorionic gonadotropin produced by the invasive trophoblast but not the villous trophoblast promotes cell invasion and is down-regulated by peroxisome proliferator-activated receptor-gamma. Endocrinology. 2007;148(10):5011–5019. doi: 10.1210/en.2007-0286Handschuh K., Guibourdenche J., Tsatsaris V., et al. Human chorionic gonadotropin produced by the invasive trophoblast but not the villous trophoblast promotes cell invasion and is down-regulated by peroxisome proliferator-activated receptor-gamma // Endocrinology. 2007. Vol. 148, N 10. P. 5011–5019. doi: 10.1210/en.2007-0286Hung TH, Shau WY, Hsieh CC, et al. Risk factors for placenta accreta. Obstet Gynecol. 1999;93(4):545–550. doi: 10.1016/s0029-7844(98)00460-8Hung T.H., Shau W.Y., Hsieh C.C., et al. Risk factors for placenta accreta // Obstet Gynecol. 1999. Vol. 93, N 4. P. 545–550. doi: 10.1016/s0029-7844(98)00460-8Dreux S, Salomon LJ, Muller F, Goffinet F, Oury JF; ABA Study Group, Sentilhes L. Second-trimester maternal serum markers and placenta accreta. Prenat Diagn. 2012;32(10):1010–1012. doi: 10.1002/pd.3932Dreux S., Salomon L.J., Muller F., Goffinet F., Oury J.F.; ABA Study Group, Sentilhes L. Second-trimester maternal serum markers and placenta accreta // Prenat Diagn. 2012. Vol. 32, N 10. P. 1010–1012. doi: 10.1002/pd.3932Zhou J, Li J, Yan P, et al. Maternal plasma levels of cell-free β-HCG mRNA as a prenatal diagnostic indicator of placenta accrete. Placenta. 2014;35(9):691–655. doi: 10.1016/j.placenta.2014.07.007Zhou J., Li J., Yan P., et al. Maternal plasma levels of cell-free β-HCG mRNA as a prenatal diagnostic indicator of placenta accrete // Placenta. 2014. Vol. 35, N 9. P. 691–695. doi: 10.1016/j.placenta.2014.07.007Berezowsky A, Pardo J, Ben-Zion M, Wiznitzer A, Aviram A. Se cond Trimester Biochemical Markers as Possible Predictors of Pathological Placentation: A Retrospective Case-Control Study. Fetal Diagn Ther. 2019;46(3):187–192. doi: 10.1159/000492829Berezowsky A., Pardo J., Ben-Zion M., Wiznitzer A., Aviram A. Second Trimester Biochemical Markers as Possible Predictors of Pathological Placentation: A Retrospective Case-Control Study // Fetal Diagn Ther. 2019. Vol. 46, N 3. P. 187–192. doi: 10.1159/000492829Guibourdenche J, Handschuh K, Tsatsaris V, et al. Hyperglycosylated hCG is a marker of early human trophoblast invasion. J Clin Endocrinol Metab. 2010;95(10):E240–E244. doi: 10.1210/jc.2010-0138Guibourdenche J., Handschuh K., Tsatsaris V., et al. Hyper glycosylated hCG is a marker of early human trophoblast invasion // J Clin Endocrinol Metab. 2010. Vol. 95, N 10. P. E240–E244. doi: 10.1210/jc.2010-0138Al-Khan A, Youssef YH, Feldman KM, et al. Biomarkers of abnormally invasive placenta. Placenta. 2020;91:37–42. doi: 10.1016/j.placenta.2020.01.007Al-Khan A., Youssef Y.H., Feldman K.M., et al. Biomarkers of abnormally invasive placenta // Placenta. 2020. Vol. 91. P. 37–42. doi: 10.1016/j.placenta.2020.01.007Einerson BD, Straubhar A, Soisson S, et al. Hyperglycosylated hCG and Placenta Accreta Spectrum. Am J Perinatol. 2019;36(1):22–26. doi: 10.1055/s-0038-1636501Einerson B.D., Straubhar A., Soisson S., et al. Hyperglycosylated hCG and Placenta Accreta Spectrum // Am J Perinatol. 2019. Vol. 36, N 1. P. 22–26. doi: 10.1055/s-0038-1636501Waller DK, Lustig LS, Smith AH, Hook EB. Alpha-fetoprotein: a biomarker for pregnancy outcome. Epidemiology. 1993;4(5):471–476. doi: 10.1097/00001648-199309000-00014Waller D.K., Lustig L.S., Smith A.H., Hook E.B. Alpha-fetoprotein: a biomarker for pregnancy outcome // Epidemiology. 1993. Vol. 4, N 5. P. 471–476. doi: 10.1097/00001648-199309000-00014Oztas E, Ozler S, Caglar AT, Yucel A. Analysis of first and second trimester maternal serum analytes for the prediction of morbidly adherent placenta requiring hysterectomy. Kaohsiung J Med Sci. 2016;32:579–585. doi: 10.1016/j.kjms.2016.08.011Oztas E., Ozler S., Caglar A.T., Yucel A. Analysis of first and second trimester maternal serum analytes for the prediction of morbidly adherent placenta requiring hysterectomy // Kaohsiung J Med Sci. 2016. Vol. 32, N 11. P. 579–585. doi: 10.1016/j.kjms.2016.08.011Ersoy AO, Oztas E, Ozler S, et al. Can venous ProBNP levels predict placenta accreta? J Matern Fetal Neonatal Med. 2016;29(24):4020–4024. doi: 10.3109/14767058.2016.1152576Ersoy A.O., Oztas E., Ozler S., et al. Can venous ProBNP levels predict placenta accreta? // J Matern Fetal Neonatal Med. 2016. Vol. 29, N 24. P. 4020–4024. doi: 10.3109/14767058.2016.1152576Shainker SA, Silver RM, Modest AM, et al. Placenta accreta spectrum: biomarker discovery using plasma proteomics. Am J Obstet Gynecol. 2020;223(3):433.e1–433.e14. doi: 10.1016/j.ajog.2020.03.019Shainker S.A., Silver R.M., Modest A.M., et al. Placenta accreta spectrum: biomarker discovery using plasma proteomics // Am J Obstet Gynecol. 2020. Vol. 223, N 3. P. 433.e1–433.e14. doi: 10.1016/j.ajog.2020.03.019